Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT01749787

Public ClinicalTrials.gov record NCT01749787. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis

Study identification

NCT ID
NCT01749787
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Protalex, Inc.
Industry
Enrollment
61 participants

Conditions and interventions

Interventions

  • PRTX-100 at 1.5 mcg/kg Drug
  • PRTX-100 at 3.0 mcg/kg Drug
  • PRTX-100 at 6.0 mcg/kg Drug
  • PRTX-100 at 12.0 mcg/kg Drug
  • PRTX-100 at 240 mcg Drug
  • Placebo Drug
  • PRTX-100 at 420 mcg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2012
Primary completion
Jul 31, 2014
Completion
Jul 31, 2014
Last update posted
Dec 22, 2014

2012 – 2014

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Protalex Investigative Site Los Angeles California 90036
Protalex Investigational Site Sarasota Florida 34239
Protalex Investigational Site Coeur d'Alene Idaho 83814
Protalex Investigational Site Anderson Indiana 46011
Protalex Investigational Site Albuquerque New Mexico 87102
Protalex Investigational Site Salisbury North Carolina 28144
Protalex Investigational Site Duncansville Pennsylvania 16635
Protalex Investigational Site Allen Texas 75013

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01749787, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01749787 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →